VERTEX PHARMACEUTICALS INC / MA 8-K

What Happened

• Vertex Pharmaceuticals announced that its Board approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan on March 27, 2026, and shareholders approved the Plan at the annual meeting held May 13, 2026. The 2026 Plan replaces the Company’s 2013 Stock and Option Plan.
• At the May 13, 2026 annual meeting, shareholders also elected ten directors, ratified Ernst & Young LLP as the Company’s independent auditor for 2026, voted on the company’s 2025 executive compensation (advisory), and voted on a shareholder proposal regarding the right to act by written consent.

Key Details

• 2026 Stock and Option Plan: Approved by shareholders with votes of 216,097,268 For; 6,523,460 Against; 376,908 Abstain; 10,337,217 Non‑Votes.
• Director elections: Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry were elected. Example tallies: Sangeeta Bhatia — 221,280,173 For / 1,624,141 Against; Bruce Sachs — 209,717,815 For / 13,186,265 Against.
• Auditor ratification: Ernst & Young LLP ratified as independent registered public accounting firm — 223,514,070 For; 9,597,395 Against; 223,388 Abstain.
• Say-on-pay (advisory): 207,918,843 For; 14,522,776 Against; 556,017 Abstain.
• Shareholder proposal on written consent: Approved with 126,892,696 For; 95,756,148 Against; 348,792 Abstain.

Why It Matters

• Approval of the 2026 Stock and Option Plan authorizes new equity awards that will be used for employee and executive compensation; investors should monitor future proxy disclosures and filings for details on award size and potential dilution.
• Re-election of the board and ratification of the auditor reflect shareholder support for current governance and oversight; the advisory approval of executive compensation and the approved written‑consent proposal indicate shareholders’ views on pay and governance procedures.
• These voting outcomes are material governance events that can affect executive incentives, share issuance, and investor perceptions; review future SEC filings and the Company’s proxy statement for more detail on plan mechanics and potential financial impacts.